

The SPARTAN Study

A clinical research study for patients whose prostate cancer has not spread beyond the prostate is now enrolling

Aragon Pharmaceuticals is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The purpose of the SPARTAN study is to evaluate the safety and effectiveness of an investigational drug in delaying prostate cancer from spreading beyond the prostate. This study is enrolling patients with prostate cancer who, despite treatment, have rising blood prostate-specific antigen (PSA) levels. All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and the investigational medication will be given to 2 out of every 3 study participants.

To learn more about the SPARTAN Study and to find out if you may be eligible, please visit: **www.clinicaltrials.gov**

Study Identifier: NCT01946204

Aragon Pharmaceuticals, Inc.

Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson and provides various services to its affiliate, Aragon Pharmaceuticals, Inc.